Blood test and imaging aim to spot nerve damage before symptoms worsen
NCT ID NCT05311488
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared different ways to detect early nerve damage in people with hereditary TTR amyloidosis, a condition that can cause progressive nerve problems. Researchers used blood tests, skin imaging, and standard nerve exams in 47 participants. The goal was to see which tools work best for catching nerve damage early, which could help start treatment sooner.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to earlier diagnosis of nerve damage in people with hereditary TTR amyloidosis, allowing for earlier treatment.
- What could go wrong
- This is a small, completed study focused on comparing diagnostic tools, not testing a treatment. The results may not apply to all patients or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
47 people
The number who actually took part.
- Started
-
Feb 2022
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
ATTRv symptomatic, asymptomatic and control.
- Ages
-
30 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Patients with known TTR mutations and neuropathy 1. Patients with TTR mutation and no symptoms within less than 10 years of typical onset of disease 2. Age criteria must meet the following: * Non V122I mutations, Age 40 or older. * V122 I mutations, 55 or older. Healthy persons without neuropathy 1. The following distribution of age ranges will be considered when enrolling healthy participants: * 5 patients age 30-40 * 5 patients age 40-50 * 5 patients age 50-60 * 5 patients age 60-70 2. Healthy control subjects for this study are defined as subjects with no symptoms of neuropathy or risk factors for neuropathy such as family history of hereditary neuropathy, chemotherapy, diabetes, autoimmune disease, or vitamin deficiency. Their status will be verified by medical records review. Exclusion Criteria: 1. Patients with neuropathy other than TTR amyloid 2. Subjects with risk factors for neuropathy (diabetes, history of neuropathy in the family, neurotoxic drugs) or with neurological disorder associated with elevated NFL
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hereditary amyloidosis, transthyretin-related are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.